Larvol Delta - 4D-pharma-Announces-Positive-Interim-Results-from-the-Phase-III-Study-of-the-Combination-of-MRx0518-and-KEYTRUDA-pembrolizumab-for-the-Treatment-of-Renal-Cell-Carcinoma

Keytruda (pembrolizumab) - Merck (MSD)

MRx0518 - 4D Pharma

https://www.businesswire.com/news/home/20220323005207/en/4D-pharma-Announces-Positive-Interim-Results-from-the-Phase-III-Study-of-the-Combination-of-MRx0518-and-KEYTRUDA%C2%AE-pembrolizumab-for-the-Treatment-of-Renal-Cell-Carcinoma

Mar 26, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next